Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…
Abstract Number: 0614 • ACR Convergence 2024
Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient
Background/Purpose: Improving quality of life (QoL) is one of the key targets when treating systemic lupus erythematosus (SLE) patients. The Lupus impact Tracker (LIT) is…
Abstract Number: 0632 • ACR Convergence 2024
Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Tyler Cepica¹, Lillian Xie², Daniella Faden², Caroline Stone³, Victoria Werth⁴ and Benjamin Chong⁵, ¹University of Texas Southwestern Medical School, Benbrook, TX, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Phiiladelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A)…
Abstract Number: 0651 • ACR Convergence 2024
Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
Jung-Min Shin¹, Jiyoung Lee², Hye-Soon Lee³, Sang-Cheol Bae³ and So-Young Bang³, ¹Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
buddhika Jayaratna¹, Pasan Serasinghe², Louise Nel³, Sahil Jain³, Shrish Sangle², Begona Lopez¹, Giovanni Sanna², Michelle Fernando¹ and David DCruz⁴, ¹Guys & St Thomas NHS Foundation Trust, London, United Kingdom, ²Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, ³Guys and St Thomas' Hospital, London, United Kingdom, ⁴The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
Abstract Number: 0837 • ACR Convergence 2024
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
Yuanxuan Xia¹, Jin Liu¹, Alexander Pearlman¹, Brian Mog¹, Elana Shaw¹, Kyle J. Kaeo¹, Colin Gliech¹, Brock Moritz¹, Tolulope Awosika¹, Sarah DiNapoli¹, Stephanie Glavaris¹, Jiaxin Ge¹, Tushar Nichakawade¹, Nikita Marcou¹, Suman Paul¹, Drew Pardoll¹, Chetan Bettegowda¹, Daniel Goldman², Michelle Petri², Antony Rosen¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Available drugs to treat autoimmune diseases are indiscriminate, suppressing self-reactive and protective immune responses alike. This lack of therapeutic precision results in infection and…
Abstract Number: 1026 • ACR Convergence 2024
Healthcare Utilization and Childhood Opportunity Index in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Julia Harris¹, Ashley Cooper² and Luke Harris², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are chronic autoimmune diseases that can be complicated by significant morbidity. There are also known…
Abstract Number: 1256 • ACR Convergence 2024
Higher Disease Activity in Pediatric Systemic Lupus Erythematosus Is Associated with a Greater Desire for Social Health Education: An Unmet Need in Pediatric Rheumatology
Kaitlin Kirkpatrick, Melodee Liegl, Ke Yan and Sara Sabbagh, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: There is limited evidence on the educational needs and preferences of caregivers and adolescents and young adults (AYA) with rheumatic disease (RD) regarding the…
Abstract Number: 1282 • ACR Convergence 2024
Investigating the Genetics of Depression and Anxiety in Children and Adolescents with and Without Systemic Lupus Erythematosus
Indrani Das¹, Nicholas Gold², Christie Burton¹, Jennifer Crosbie¹, JingJing Cao¹, Daniela Dominguez¹, Sefi Kronenberg³, Lawrence Ng², Alene Toulany¹, Hiu-Ki Rachel Tran¹, Gwyneth Zai⁴, Andrea Knight⁵ and Linda Hiraki², ¹The Hospital for Sick Children, Toronto, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Holland-Bloorview Kids Rehabilitation Hospital., Toronto, Canada, ⁴Centre for Addiction and Mental Health, Toronto, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) have a higher prevalence of depression and anxiety compared to healthy peers. Patients with cSLE also have…
Abstract Number: 1496 • ACR Convergence 2024
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Loqmane seridi¹, Steven Leonardo², Brittney Scott³, Robert Gordon¹, cathye shu¹, Kaiyin Fei¹, Kim Lo³, Anne Stevens¹ and Sheng Gao³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
Abstract Number: 1512 • ACR Convergence 2024
Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: The systemic immune-inflammation index (SII) has been linked to inflammatory and immune responses, with research indicating its impact on rheumatoid arthritis (RA). However, its…
Abstract Number: 1529 • ACR Convergence 2024
Systemic Lupus Erythematous and Neuromyelitis Optica Overlap and Risk of Infection in Hospitalized Patients
Elizabeth Fagin¹, Wei Chapman², fares Saliba³ and Eugenio Capitle⁴, ¹Staten Island University Hospital, Teaneck, ²Staten Island University Hospital, Staten Island, ³Staten Island University Hospital, Staten Island, NY, ⁴University Hospital, Newark
Background/Purpose: Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder that can coexist with systemic lupus erythematous (SLE). Given the immunosuppressive nature of SLE, it is…
Abstract Number: 1549 • ACR Convergence 2024
Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Celestine He¹, Zhonghan Li¹, Sumanth Chennareddy² and Chrisanna Dobrowolski³, ¹Icahn School of Medicine, Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Treatment of Systemic Lupus Erythematosus (SLE) has evolved substantially in the past decade. In 2011, the FDA approved belimumab, the first targeted monoclonal antibody…
Abstract Number: 1688 • ACR Convergence 2024
Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
Jack Arnold¹, Lucy Carter¹, Yuzaiful Yusof², Zoe Wigston², Daniel Toro Dominguez³, Samuel Relton⁴, Guillermo Barturen⁵, Marta Alarcon-Riquelme⁶ and Edward Vital⁷, and PRECISESADS consortium, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ³Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, ⁴Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ⁵Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom
Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
Abstract Number: 1780 • ACR Convergence 2024
Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus
Laura Lewandowski¹, Linda Hiraki², Christiaan Scott³, Ana Barrera-Vargas⁴, Diana Gómez-Martin⁵, Michael Ombrello⁶, Ivona Aksentijevich⁷, Zuoming deng⁸, Anthony Musolf⁹, Subrata Paul¹⁰, Dan Hupalo¹¹, Clifton Dalgard¹¹, Sarfaraz Hasni¹², Earl Silverman¹³ and Mariana Kaplan¹⁴, ¹NIAMS, NIH, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatric Rheumatology, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, ⁵INCMNSZ, Mexico, Distrito Federal, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁹Computational and Statistical Genomics Branch, NHGRI, NIH, Baltimore, MD, ¹⁰Collaborative Bioinformatics Resource, NIAID, NIH, Bethesda, MD, ¹¹The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, ¹²National Institutes of Health, Bethesda, MD, ¹³Silverman, Toronto, ON, Canada, ¹⁴NIAMS/NIH, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease. Childhood-onset SLE (cSLE) patients have younger disease onset and more severe disease than adults,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].